Related to Sanofi and Genzyme Report New Positive Data from First Phase III Study with MS Drug

• Sanofi to Investigate Immune Design’s TLR-4 Agonist Platform in the Field of Allergy
  
• Genzyme and Cystic Fibrosis Foundation Therapeutics Ink Research Deal
  
• Foundation and Sanofi Sign Deal for Cancer Biomarkers and Companion Diagnostics
  
• Median Provides Sanofi with Image Interpretation Software for Phase II Lung Cancer Study
  
• Sanofi to Shutter Genzyme's R&D Site in Cambridge, U.K.
  
• MJFF Sponsors Phase Ib Trial with Sanofi's Parkinson Disease Candidate
  
• FDA Approves Genzyme's Multiple Sclerosis Drug
  
• Phase III Results Promising for Diabetes, Gaucher, Atrial Fibrillation Drugs
  
• Yeast Strain Rises to Fight Malaria
  
• NextBio, Sanofi Team Up to Incorporate Omics Data into R&D
  
• Genzyme Acquires MS and CLL Therapy as well as Two More Oncology Products from Bayer
  
• Sanofi-Aventis’ Teriflunomide Comes Up Trumps in Two-Year Phase III MS Trial
  
• Genzyme Reports Data from Late-Stage MS Study
  
• Genzyme’s MS Therapy Teriflunomide Shows Positive Initial Results in Third Phase III Trial
  
• Novel Platform for Immunotherapies Created
  
• Bayer Inks Commercialization Agreement with Genzyme Worth up to $2B
  
• Sanofi-Aventis and Genzyme Finally Agree to $20.1B plus CVR Acquisition Deal
  
• Genzyme’s mAb for Multiple Sclerosis Succeeds in Second Phase III Trial
  
• Sanofi and Genzyme Report Positive New Data from Phase III Multiple Sclerosis Study
  
• Sanofi and Genzyme Report Positive Data from Pivotal Trial Comparing Alemtuzumab with Rebif in MS